University of Oklahoma Health: Clinical Trial to Evaluate Immunotherapy Drug for Stage I Non-Small Cell Lung Cancer Following Surgery
July 01, 2026
July 01, 2026
OKLAHOMA CITY, Oklahoma, July 1 -- The University of Oklahoma Health campus issued the following news:
* * *
Clinical Trial to Evaluate Immunotherapy Drug for Stage I Non-Small Cell Lung Cancer Following Surgery
Muhammad Furqan, M.D., professor of hematology-oncology at the University of Oklahoma College of Medicine and Associate Director of Clinical Research at OU Health Stephenson Cancer Center, is leading a national clinical trial evaluating whether immu . . .
* * *
Clinical Trial to Evaluate Immunotherapy Drug for Stage I Non-Small Cell Lung Cancer Following Surgery
Muhammad Furqan, M.D., professor of hematology-oncology at the University of Oklahoma College of Medicine and Associate Director of Clinical Research at OU Health Stephenson Cancer Center, is leading a national clinical trial evaluating whether immu . . .